Claims for Patent: 9,687,485

Summary for Patent: 9,687,485

Title:	Combination therapy with glutaminase inhibitors
Abstract:	The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kinase inhibitor), a mitotic inhibitor, a DNA-modifying agent, or a cytidine analog. The invention further relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases that are resistant to one or more anticancer agents.
Inventor(s):	Steggerda; Susanne M. (San Francisco, CA), MacKinnon; Andrew L. (San Francisco, CA), Rodriguez; Mirna L. (San Jose, CA), Zhang; Dong (San Jose, CA), Parlati; Francesco (San Francisco, CA)
Assignee:	Calithera Biosciences, Inc. (South San Francisco, CA)
Application Number:	14/738,279
Patent Claims:	1. A method of treating lung cancer in a subject, comprising conjointly administering to said subject a compound of Formula (II) ##STR00034## or a pharmaceutically acceptable salt thereof; and an anticancer agent, wherein the anticancer agent is erlotinib. 2. The method of claim 1, wherein conjointly administering the compound of Formula (II) and the anticancer agent provides improved efficacy relative to individual administration of the glutaminase inhibitor or anticancer agent as a single agent. 3. The method of claim 2, wherein conjointly administering the anticancer agent and the compound of Formula (II) provide an additive effect. 4. The method of claim 2, wherein conjointly administering the anticancer agent and the compound of Formula (II) provide a synergistic effect. 5. The method of claim 1, wherein the anticancer agent and the compound of Formula (II) are administered simultaneously. 6. The method of claim 1, wherein the anticancer agent is administered within about 5 minutes to within about 168 hours prior or after of the compound of Formula (II). 7. The method of claim 1, wherein the lung cancer is resistant to erlotinib. 8. The method of claim 1, further comprising conjointly administering one or more additional chemotherapeutic agents. 9. The method of claim 8, wherein the one or more additional chemotherapeutic agents includes aminoglutethimide, amsacrine, anastrozole, asparaginase, Bacillus Calmette-Guerin vaccine (bcg), bicalutamide, bleomycin, bortezomib, buserelin, busulfan, campothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, or vinorelbine. 10. The method of claim 1, wherein the method further comprises administering one or more non-chemical methods of cancer treatment. 11. The method of claim 10, wherein the one or more non-chemical methods comprise radiation therapy. 12. The method of claim 10, wherein the one or more non-chemical methods comprise surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination of the foregoing. 13. The method of claim 7, wherein the lung cancer is non-small cell lung cancer. 14. The method of claim 1, wherein the lung cancer is non-small cell lung cancer. 15. A method of treating multiple myeloma, triple negative breast cancer, non-small cell lung cancer, or renal cell carcinoma in a subject, comprising conjointly administering to said subject a compound of Formula (II) ##STR00035## or a pharmaceutically acceptable salt thereof; and everolimus. 16. The method of claim 15, wherein the method is a method of treating non-small cell lung cancer or renal cell carcinoma. 17. The method of claim 16, wherein the method is a method of treating renal cell carcinoma.

Details for Patent 9,687,485

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-06-13
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2034-06-13
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2034-06-13